ClinicalTrials.gg
Active, not recruitingNCT05644561Updated Apr 17, 2026

Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis

A Phase 3 interventional study of Ravulizumab in Generalized Myasthenia Gravis and gMG, sponsored by Alexion Pharmaceuticals, Inc.. Active, not recruiting at 11 sites in 5 countries. Per ClinicalTrials.gov, last updated 2026-04-17.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Myasthenia Gravis by AstraZeneca — 8 open to participants now, 11 under way, 4 of them phase 3. Myasthenia Gravis · AstraZeneca.

Enrollment
10th of 13
12 · median 20
Started
2023
the only one that year
Phase 3
9 of 19
2 open now
Primary completion
2026-07
later than 1 of 10 live
Registered
10th of 19
by date

Among the 19 studies in Myasthenia Gravis by AstraZeneca, this one is the 10th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2023, is one of 9 in phase 3, reaches primary completion later than 1 of the 10 other live ones, and was the 10th registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

8 of the 19 studies in Myasthenia Gravis by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Myasthenia Gravis by AstraZeneca, or all of them as a file.
02

Study summary

The primary purpose of this study is to characterize the pharmacokinetics and pharmacodynamics of treatment with ravulizumab intravenous infusion in pediatric participants with gMG.

03

Conditions studied

  • Generalized Myasthenia Gravis
  • gMG

Browse trials for

Keywords

  • Generalized Myasthenia Gravis
  • gMG
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of gMG confirmed by a positive serologic test for anti-AChR antibodies (Abs) obtained at Screening and/or during Screening Period
  • Myasthenia Gravis Foundation of America (MGFA) Clinical Classification of Class II to Class IV at Screening
  • Participants receiving treatment must be on a stable dosing regimen of adequate duration prior to Screening and during the Screening Period.
  • Eculizumab-experienced participants must have been enrolled and treated with eculizumab in Study ECU-MG-303 for at least 6 months (180 days) and must have been on a stable dose for ≥ 2 months (60 days) prior to Screening.
  • All participants must be vaccinated against meningococcal infection

Exclusion criteria

Exclusion Criteria:

Medical Conditions

  • Any untreated thymic , carcinoma, or thymoma.
  • Participants with a history of treated benign thymoma
  • History of thymectomy, thymomectomy, or any thymic surgery within the 12 months prior to Screening
  • History of N meningitidis infection
  • Known to be (HIV) positive
  • History of unexplained infections
  • Known or suspected history of drug or alcohol abuse or dependence within 1 year prior to the start of the Screening Period
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Ravulizumab Intravenous (IV) Infusion

    All participants will receive a weight-based loading dose of ravulizumab IV on Day 1, followed by weight-based maintenance dose of ravulizumab on Day 15 and once every 8 weeks (q8w) thereafter for participants weighing ≥ 20 kg, or once every 4 weeks (q4w) for participants weighing \< 20 kg, for a total of 122 weeks of treatment.

    Drug: Ravulizumab

Interventions

  • Ravulizumab will be administered by intravenous (IV) infusion.

06

What researchers measure

Primary outcomes

  1. Serum Concentration of Ravulizumab

    Time frame: Day 1 predose through Week 18 predose

  2. Serum Free C5 Concentration

    Time frame: Day 1 predose through Week 18 predose

Secondary outcomes

  1. Change From Baseline in The Quantitative Myasthenia Gravis (QMG) Total Score at Up to Week 18

    Time frame: Baseline, Up to Week 18

  2. Change From Baseline in Myasthenia Gravis-Activities Of Daily Living (MG-ADL) Total Score at Up to Week 18

    Time frame: Baseline, Up to Week 18

  3. Change From Baseline in Myasthenia Gravis Composite (MGC) Score at Up to Week 18

    Time frame: Baseline, Up to Week 18

  4. Change in Status from Week 10 in Myasthenia Gravis Foundation of America Postintervention Status (MGFA-PIS) as Assessed by the Investigator or Neurologist at Up to Week 18

    Time frame: Week 10, Up to Week 18

  5. Change from Baseline in Neurology Quality of Life (Neuro QoL) Pediatric Fatigue Score at Up to Week 18

    Participants ≥8 years of age will be evaluated.

    Time frame: Baseline, Up to Week 18

  6. Change from Baseline in Patient-reported Outcomes Measurement Information System (PROMIS) Parent Proxy - Fatigue Score at Up to Week 18

    Participants \<8 years of age will be evaluated.

    Time frame: Baseline, Up to Week 18

  7. Number of Participants With ≥5-point Reduction Compared to Baseline in the QMG Total Score Over Time Through Week 18

    Time frame: Baseline through Week 18

  8. Number of Participants With ≥3 point Reduction Compared to Baseline in the MG-ADL Total Score Over Time Through Week 18

    Time frame: Baseline through Week 18

  9. Number of Participants That Improve or Remain Stable in QMG Total Score at Week 18 Compared to Baseline

    Stable is defined as a ±5-point change from Baseline.

    Time frame: Baseline through Week 18

  10. Number of Participants That Improve or Remain Stable in MG ADL Total Score at Week 18 Compared to Baseline

    Stable is defined as a ±3-point change from baseline.

    Time frame: Baseline through Week 18

  11. Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events

    Time frame: Baseline up to Week 126 (8 weeks after last dose of study drug)

  12. Number of Participants With Anti-Drug Antibody (ADA) at Week 18

    Time frame: Baseline through Week 18

07

Study locations

11 sites
  • Research Site
    Los Angeles, California 90078, United States
  • Research Site
    Boston, Massachusetts 02115, United States
  • Research Site
    Chapel Hill, North Carolina 27514, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    Milan, 20133, Italy
  • Research Site
    Roma, 00165, Italy
  • Research Site
    Torino, 10126, Italy
  • Research Site
    Itabashi-ku, 173-0003, Japan
  • Research Site
    Belgrade, 11000, Serbia
  • Research Site
    Belgrade, 11070, Serbia
  • Research Site
    Bern, 3010, Switzerland
08

References and documents

Individual participant data

Plan to share: Yes — Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Jul 2026, 36 months after the start.

Of 43 industry-sponsored phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's planned 36 months is above that.

Counting every sponsor, half of 52 studies reached it within 30 months; a quarter within 20 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2022
First posted
Dec 9, 2022
StartActual
Jun 24, 2023
Primary completionEst.
Jul 15, 2026
CompletionEst.
Jun 30, 2028
Last update
Apr 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05644561
Responsible party
Sponsor
First posted
Dec 9, 2022
Start date
Jun 24, 2023
Primary completion
Jul 15, 2026 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Apr 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ravulizumab

Start the discussion